drugset / Trial / NCT07439848
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis
Phase 1/2
Recruiting
15 enrolled
PT. Prodia Stem Cell Indonesia
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study was conducted to determine the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSC) and Secretome in severe ARDS patients. The study is a randomized control trial - double blind, which has 3 arms intervention namely, Control treatment, UC-MSC treatment, and UC-MSC and Secretome treatment.
Timeline
- Start
- 2023-12-25
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secretome | Other / unclassified | 2 ml | Intranasal |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1e+07 cells/kg | Intravenous |